In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Teva's Senior Vice President emphasized the ... and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk ...

Teva Cautionary Note Regarding Forward-Looking ... and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite facing operating loss and margin pressures.

New York, New York-- (Newsfile Corp. - February 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against FTAI Aviation Ltd. (NASDAQ: FTAI) and ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease <li /> New detailed data from ...

Q4 2024 Earnings Call Transcript February 19, 2025 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Growth stocks can help to supercharge your investment portfolio and boost your retirement fund. The key, however, is to ...